Anne Weng Ekmann-Gade1, Claus Kim Hogdall2, Svend Aage Engelholm3, Carsten Lindberg Fago-Olsen2. 1. Department of Gynecology, The Juliane Marie Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark anne.weng.ekmann-gade@regionh.dk. 2. Department of Gynecology, The Juliane Marie Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Oncology, The Finsen Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC). PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity. RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005). CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy. Copyright
BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC). PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity. RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005). CONCLUSION:NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy. Copyright